|
市場調查報告書
大日本住友製藥：製藥企業分析報告
Dainippon Sumitomo: Pipeline * Products * Performance * Potential
|
大日本住友製藥：製藥企業分析報告 是由出版商Espicom Business Intelligence在2010年01月所出版的。
這份英文市場調查報告書包含Pages: 84 價格從美金1040起跳。
Abstract
Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company,
headquartered in Osaka, which has resulted from the merger of Dainippon
Pharmaceutical (which acts as the surviving company) and Sumitomo
Pharmaceutical (a division of Sumitomo Chemical).
The merger was finalised and operations began on 1st October 2005, with the
new company becoming the fifth largest pharmaceutical company in Japan. DSP is
listed as a consolidated subsidiary of Sumitomo Chemical, which owns 50.1 per
cent of the outstanding shares.
Since the merger, DSP is active in a range of therapeutic areas, principally
Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System
(CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus
its product base on CNS diseases and the treatment of diabetes and associated
complications.
This new strategic analysis report Dainippon Sumitomo: Pipeline " Products "
Performance " Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Performance
- Company Strategy
- Acquisitions
- Key Agreements
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CARDIOVASCULAR
- Marketed Products
- Amlodin
- Avapro
- Ephedrine Nagai
- ProRenal
- Others
- R&D Projects
- Growth Forecast
- ONCOLOGY/INFECTION
- Marketed Products
- AmBisome
- Meropen/Merrem
- Others
- R&D Projects
- Growth Forecast
- GASTROINTESTINAL
- Marketed Products
- Growth Forecast
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Excegran/Exogran/Zonegran/Tremode/Trerief
- Lonasen
- Others
- R&D Projects
- Lurasidone
- Ranirestat
- Growth Forecast
- INFLAMMATION/ALLERGY
- Marketed Products
- R&D Projects
- Growth Forecast
- DIABETES
- Marketed Products
- R&D Projects
- DSP-3235
- DSP-7238
- DSP-8658
- Repaglinide
- Growth Forecast
- OTH ER
- Marketed Products
- R&D Projects
- SMP-986
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Almirall Prodesfarma SA
- Astellas Pharma
- AstraZeneca
- Bristol-Myers Squibb
- Chelsea Therapeutics International Ltd
- Conforma Therapeutics Corporation
- Daewoong Pharmaceutical
- Eisai
- Gilead Sciences
- Idenix Pharmaceuticals Inc
- Kissei Pharmaceutical Co Ltd
- Kyorin Pharmaceutical Co Ltd
- Merck KGaA
- Mitsubishi Tanabe Pharma Corp
- Neurocrine Biosciences Inc
- Novo Nordisk
- Ono Pharmaceutical
- Pfizer
- Protez Pharmaceuticals Inc
- PsychoGenics Inc
- Recordati
- sanofi-aventis
- Schering-Plough
- Servier
- Sunesis Pharmaceuticals Inc
- Torii Pharmaceutical
- APPENDIX 4 - INFRASTRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales By Business Area
- Operating Income By Business Area
- Identifiable Assets By Business Area
- Sales by Destination
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular Products, 2009
- Major Oncology/Infection Products, 2009
- Major Gastrointestinal Products, 2009
- Major Central Nervous System Products, 2009
- Major Inflammation/Allergy Product, 2009
- Major Diabetes Products, 2009
- Other Products, 2009
INDEX OF CHARTS
- Sales By Business Area
- Operating Income By Business Area
- Sales of Top Ten Products (2004A-2014E)
- Top Ten Selling Products, 2009
- Domestic R&D Pipeline
- Overseas R&D Pipeline
- Amlodin Sales (2004A-2014E)
- Avapro Sales (2009A-2015E)
- ProRenal Sales (2004A-2014E)
- Ambisome Sales (2007A-2014E)
- Meropen Sales (2004A-2014E)
- Gasmotin Sales (2004A-2014E)
- Excegran Sales (2004A-2014E)
- Lonasen Sales (2009A-2014E)
- Ebastel Sales (2004A-2014E)
- QVAR Sales (2004A-2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
